Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
GSK is moving its mRNA-based seasonal flu vaccine into a late-stage clinical trial after promising mid-stage results. The candidate generated stronger immune responses than both standard- and high-dose flu shots currently on the market. It's a significant step forward for mRNA technology beyond COVID-19.
GSK is taking its mRNA-based seasonal influenza vaccine candidate to the next level. The pharma giant announced it will advance the shot into a late-stage (Phase 3) trial after mid-stage data showed it produced stronger immune responses compared to currently approved standard- and high-dose flu vaccines. The move signals growing confidence in mRNA technology as a platform for tackling infectious diseases beyond COVID-19.
This development puts GSK in the race alongside other players exploring next-generation flu vaccines, with mRNA's speed and flexibility offering potential advantages in keeping up with rapidly evolving influenza strains.
Key Takeaways:
Why it matters: If the late-stage trial succeeds, GSK's mRNA flu vaccine could redefine the standard of care for seasonal influenza — offering stronger protection and potentially faster updates to match new strains, benefiting millions of people vaccinated each year.
